Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Drug Deliv ; 23(4): 1152-62, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-25586675

RESUMEN

BACKGROUND: Epirubicin-HCl is highly efficient for breast cancer management at a concentration of 60-90 mg/m(2). However, its application is limited due to cumulative dose-dependent cardio-toxicity. PURPOSE: The main aim of this study was to formulate breast cancer-targeted liposomal carrier by surface conjugation of transferrin to minimize cardio-toxicity of drug along with improved pharmacokinetic profile. METHOD: Liposomes were formulated by ethanol injection method using HSPC, cholesterol and DSPG and later loaded with drug by the ammonium sulfate gradient method. The formulation was characterized for physicochemical properties like size, zeta potential, entrapment efficiency, TEM; in vitro tests like electro-flocculation, hemolysis and drug release; cell line study (MCF-7 cells); in vivo studies including LD50 determination, pharmacokinetic analysis, myocardial toxicity determination and stability. RESULTS AND DISCUSSION: Optimized formulation had molar ratio of 60:30:8:2 (HSPC:Chol:DSPG:mPEG-DSPE) with entrapment efficiency ∼83%, particle size below 200 nm and zeta potential about -20 mV. In vitro studies proved non-interfering property and drug release character of formulation while cell line studies demonstrated improvement in cell uptake and thereby increased cytotoxicity of targeted formulation. The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively. Furthermore, in vivo tests validated safety and distribution profile of prepared formulations. CONCLUSION: Apt properties of prepared Epirubicin-HCl liposomal formulation warrant its clinical application in breast cancer treatment after further studies.


Asunto(s)
Neoplasias de la Mama/química , Colesterol/química , Epirrubicina/química , Lípidos/química , Células MCF-7 , Polietilenglicoles/química , Transferrina/química , Neoplasias de la Mama/fisiopatología , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Epirrubicina/farmacocinética , Femenino , Humanos , Lípidos/farmacocinética , Liposomas , Tamaño de la Partícula , Polietilenglicoles/administración & dosificación , Transferrina/farmacocinética
2.
Drug Deliv ; 22(6): 849-61, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-24725027

RESUMEN

This study was aimed to develop and evaluate p53 polyplex-loaded enteric-coated calcium pectinate microbeads for oral gene delivery as an effective novel alternative for colorectal cancer therapy. Mutation in p53 is the key event in colorectal cancer (CRC) and an important target for the treatment of CRC through gene therapy. Polymethacrylates-based non-viral vectors were evaluated for their ability to complex, protect and transfect p53 (wt) into colon cancer cell line. Polyplexes were formulated by complexation of cationic polymer with anionic pDNA at different N/P ratios. p53 polyplex-loaded calcium pectinate (CP) microbeads were prepared by ionotropic gelation of pectin with calcium chloride and coated with Eudragit® S100. In vitro release studies showed that enteric-coated CP microbeads protected the release of p53 polyplex in upper GIT with less than 10% release. In-vitro cell line studies and in vivo studies in rat showed that polymethacrylate carrier could transfect the pDNA effectively. Results of in vivo gene expression study further confirmed the ability of enteric-coated calcium pectinate microbeads to deliver pDNA specifically to rat colon. Conclusively, enteric-coated calcium pectinate microbeads released p53 polyplex specifically in colon and could serve as an effective alternative for CRC therapy.


Asunto(s)
ADN/administración & dosificación , Portadores de Fármacos/química , Genes p53 , Microesferas , Plásmidos/administración & dosificación , Ácidos Polimetacrílicos/química , Administración Oral , Animales , Cloruro de Calcio/química , Línea Celular Tumoral , Química Farmacéutica , Neoplasias Colorrectales/tratamiento farmacológico , ADN/farmacología , Liberación de Fármacos , Terapia Genética , Pectinas/química , Plásmidos/farmacología , Ratas , Comprimidos Recubiertos , Tecnología Farmacéutica , Transfección/métodos
3.
Pharm Res ; 32(3): 806-18, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24792823

RESUMEN

PURPOSE: The aim of present investigation was to effectively deliver ribonucleotide reductase subunit 1 (RRM1) targeted siRNA and assess chemo-sensitization of lung cancer cells against Gemcitabine hydrochloride. It was hypothesised that effective and selective delivery of RRM1 siRNA will help in the treatment of lung cancer chemotherapy using Gemcitabine hydrochloride by reducing drug dose and thereby, reduces dose related toxicity of Gemcitabine hydrochloride. METHODS: In this investigation, cRGD grafted siRNA nano-constructs were developed for efficient and targeted intracellular delivery of siRNA. Developed formulations were characterized for gel retardation assay, particle size, zeta potential, cryo transmission electron microscopy, serum stability, in vitro cytotoxicity, qualitative and quantitative cell uptake, gene expression, and chemo-sensitization. RESULTS: Complete complexation of siRNA with cRGD grafted nano-constructs was found at N/P ratio of 2.0. Naked siRNA was found to degrade within 6 h in presence of 50% serum while nano-constructs protected the complexed siRNA even after 24 h. RRM1 level significantly reduced when siRNA was delivered in nano-construct form as compared to naked siRNA. Pre-exposure of RRM1 siRNA decreased the IC50 value of Gemcitabine hydrochloride 5 folds in A-549 cells compared to Gemcitabine hydrochloride alone. CONCLUSION: These results suggest the application of present siRNA delivery strategy to potentiate the chemotherapeutic effect by means of chemosensitization which may be utilized for effective and thorough remission of lung cancer.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Desoxicitidina/análogos & derivados , Terapia Genética/métodos , Neoplasias Pulmonares/genética , Nanopartículas , Péptidos Cíclicos/metabolismo , Interferencia de ARN , ARN Interferente Pequeño/genética , Proteínas Supresoras de Tumor/genética , Antimetabolitos Antineoplásicos/toxicidad , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Desoxicitidina/farmacología , Desoxicitidina/toxicidad , Relación Dosis-Respuesta a Droga , Humanos , Concentración 50 Inhibidora , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Tamaño de la Partícula , Estabilidad del ARN , ARN Interferente Pequeño/metabolismo , Ribonucleósido Difosfato Reductasa , Factores de Tiempo , Transfección , Proteínas Supresoras de Tumor/metabolismo , Gemcitabina
4.
AAPS PharmSciTech ; 15(6): 1630-43, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25145330

RESUMEN

Cationic liposomes have long been used as non-viral vectors for small interfering RNA (siRNA) delivery but are associated with high toxicity, less transfection efficiency, and in vivo instability. In this investigation, we have developed siRNA targeted to RRM1 that is responsible for development of resistance to gemcitabine in cancer cells. Effect of different lipid compositions has been evaluated on formation of stable and less toxic lipoplexes. Optimized cationic lipoplex (D2CH) system was comprised of dioleoyl-trimethylammoniumpropane (DOTAP), dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), hydrogenated soya phosphocholine (HSPC), cholesterol, and methoxy(polyethyleneglycol)2000-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG2000-DSPE). D2CH lipoplexes have shown particle size (147.5 ± 2.89 nm) and zeta potential (12.26 ± 0.54 mV) characteristics essential for their in vivo use. In vitro cytotoxicity study has shown low toxicity of developed lipoplexes as compared with lipofectamine-2000 up to N/P ratio as high as 7.5. Cell uptake studies and gene expression studies have confirmed intracellular availability of siRNA. In addition, developed lipoplexes also showed ~3 times less hemolytic potential as compared with DOTAP/DOPE lipoplexes at lipid concentration of 5 mg/mL. Lipoplexes also maintained particle size less than 200 nm on exposure to high electrolyte concentration and showed >70% siRNA retention in presence of serum showing siRNA protection conferred by lipoplexes. Furthermore, in vivo acute toxicity studies in mice showed that formulation was non-toxic up to a dosage of 0.75 mg of siRNA/kg as lipoplexes and 300 mg lipid/kg as blank liposomes indicating tolerability of lipoplexes at a dose much higher than required for therapeutic use. Promising results of this study warrant further investigation of developed siRNA lipoplexes for cancer treatment.


Asunto(s)
Terapia Genética/métodos , Lípidos/química , Neoplasias/terapia , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Transfección/métodos , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Femenino , Regulación Neoplásica de la Expresión Génica , Hemólisis/efectos de los fármacos , Humanos , Lípidos/toxicidad , Liposomas , Ratones , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/patología , Tamaño de la Partícula , Estabilidad del ARN , ARN Interferente Pequeño/sangre , ARN Interferente Pequeño/química , Ribonucleósido Difosfato Reductasa , Proteínas Supresoras de Tumor/genética , Proteínas Supresoras de Tumor/metabolismo
5.
AAPS PharmSciTech ; 15(4): 845-57, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24700295

RESUMEN

Cisplatin, first (platinum) compound to be evolved as an anticancer agent, has found its important place in cancer chemotherapy. However, the dose-dependent toxicities of cisplatin, namely nephrotoxicity, ototoxicity, peripheral neuropathy, and gastrointestinal toxicity hinder its widespread use. Liposomes can reduce the toxicity of cisplatin and provide a better therapeutic action, but the low lipid solubility of cisplatin hinders its high entrapment in such lipid carrier. In the present investigation, positively charged reactive aquated species of cisplatin were complexed with negatively charged caprylate ligands, resulting in enhanced interaction of cisplatin with lipid bilayer of liposomes and increase in its encapsulation in liposomal carrier. Prepared cisplatin liposomes were found to have a vesicular size of 107.9 ± 6.2 nm and zeta potential of -3.99 ± 3.45 mV. The optimized liposomal formulation had an encapsulation efficiency of 96.03 ± 1.24% with unprecedented drug loading (0.21 mg cisplatin / mg of lipids). The in vitro release studies exhibited a pH-dependent release of cisplatin from liposomes with highest release (67.55 ± 3.65%) at pH 5.5 indicating that a maximum release would occur inside cancer cells at endolysosomal pH. The prepared liposomes were found to be stable in the serum and showed a low hemolytic potential. In vitro cytotoxicity of cisplatin liposomes on A549 lung cancer cell line was comparable to that of cisplatin solution. The developed formulation also had a significantly higher median lethal dose (LD50) of 23.79 mg/kg than that of the cisplatin solution (12 mg/kg). A promising liposomal formulation of cisplatin has been proposed that can overcome the disadvantages associated with conventional cisplatin therapy and provide a higher safety profile.


Asunto(s)
Caprilatos/química , Cisplatino/química , Liposomas/química , Animales , Línea Celular Tumoral , Química Farmacéutica/métodos , Portadores de Fármacos/química , Femenino , Humanos , Concentración de Iones de Hidrógeno , Membrana Dobles de Lípidos/química , Ratones , Tamaño de la Partícula , Fosfolípidos/química , Solubilidad
6.
J Control Release ; 182: 45-57, 2014 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-24631861

RESUMEN

Development of effective vector for intracellular delivery of siRNA has always been a challenge due to its hydrophilicity, net negative surface charge and sensitivity against nucleases in biological milieu. The present investigation was aimed to develop a novel non-viral liposomal carrier for siRNA delivery. Nano-precipitate of calcium phosphate was entrapped in liposomes composed of a neutral lipid (DPPC), a fusogenic lipid (DOPE), a PEGylated lipid (DSPE-mPEG2000) and cholesterol. siRNA was made permeable through liposomal bilayer and complexed to calcium phosphate precipitates inside the liposomes. siRNA entrapped liposomes were further grafted with cRGD to achieve targeting potential against cancer cells. More than 80% of siRNA was entrapped inside the liposomes having average particle size below 150nm. Cryo-transmission electron microscopy revealed the intra-liposomal calcium phosphate precipitation and unilamellar morphology of prepared liposomes. The viability of A549 lung cancer cells was significantly higher after treatment with siRNA entrapped liposomes as compared to Lipofectamine2000 complexed siRNA. Fluorescent intensity in lung carcinoma cells was significantly higher after exposure to fluorescent siRNA entrapped liposomes than with Lipofectamine2000, which were confirmed by both confocal microscopy and flow cytometry. Live imaging by confocal microscopy ascertained the targeting efficacy of cRGD grafted liposomes compared to naked siRNA and non-grafted liposomes. Developed liposomal formulation showed effective protection of siRNA against serum nucleases along with less haemolytic potential and excellent stability against electrolyte induced flocculation. At 5nM concentration gene expression of target protein was reduced up to 24.1±3.4% while Lipofectamine2000 reduced expression level up to 26.35±1.55%. In vivo toxicity in mice suggested admirable safety profile for developed lipid based delivery vector. These results advocate that prepared liposomal system would be of high value for intracellular delivery of siRNA.


Asunto(s)
Péptidos Cíclicos/administración & dosificación , ARN Interferente Pequeño/administración & dosificación , Transfección/métodos , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Eritrocitos/efectos de los fármacos , Femenino , Expresión Génica , Hemólisis/efectos de los fármacos , Humanos , Liposomas , Ratones , Neoplasias/tratamiento farmacológico , Péptidos Cíclicos/química , ARN Mensajero/metabolismo , ARN Interferente Pequeño/química , Ratas Sprague-Dawley , Ribonucleósido Difosfato Reductasa , Pruebas de Toxicidad Aguda , Proteínas Supresoras de Tumor/genética
7.
J Pharm Bioallied Sci ; 4(Suppl 1): S21-2, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23066191

RESUMEN

The aim of the present work was to formulate a self-microemulsifying drug delivery system (SMEDDS) containing orlistat. The oil, surfactant and co-surfactant were decided based on the solubility studies. Pseudoternary phase diagrams were plotted, microemulsification area was determined and different formulations were prepared. Particle size, zeta potential, dispersibility test and thermodynamic stability studies were measured. In-vitro dissolution test of thermodynamically stable formulations OS-B and OS-C were carried and results were compared with those of plain drug and suspension formulation. Stability studies performed indicated that formulation OS-C remained stable over 12 months period. Thus this investigation concluded that hydrophobic drugs like orlistat can be delivered effectively through the formulation of SMEDDS.

8.
Recent Pat Drug Deliv Formul ; 6(1): 45-65, 2012 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-22264188

RESUMEN

siRNA inhibits protein expression by degrading complementary mRNA sequence and hence, it is widely applicable for the treatment of various diseases where single or multiple gene knock down is necessary. Due to the severity and lethality of pulmonary diseases, siRNA has been focused for improved health in these diseases. Pulmonary accumulation of siRNA can be achieved by different means like intranasal or inhalation administration or intratracheal route which is mainly utilized for in vivo animal studies. However, various pulmonary obstacles and intracellular barriers for siRNA transport challenge this novel therapeutic moiety. Researchers have utilized different viral and non-viral delivery vectors for intracellular delivery of siRNA to knock down target mRNA. The promise of RNA interference, mediated by siRNAs, has revolutionized the prospects for modulating gene expression as a way to achieve therapeutic aims in disease treatment. This review focuses on patents describing the siRNA delivery either in naked form or along with a single/multiple delivery vectors. Many inventors have shown promising results for pulmonary utilization of siRNA and more concentration on delivery system may make this genomic approach available to the clinics soon.


Asunto(s)
Técnicas de Transferencia de Gen/normas , Enfermedades Pulmonares/genética , Enfermedades Pulmonares/terapia , Patentes como Asunto , ARN Interferente Pequeño/administración & dosificación , Administración Intranasal , Animales , Técnicas de Transferencia de Gen/tendencias , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Humanos , Pulmón/efectos de los fármacos , Pulmón/metabolismo , ARN Interferente Pequeño/genética
9.
Pharm Pat Anal ; 1(5): 577-88, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24236926

RESUMEN

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vascular system, which may lead to right-heart failure or early death in the absence of effective treatment. The current therapy for PAH mainly includes phosphodiesterase inhibitors, prostanoids and endothelin receptor antagonists. These, however, have adverse effects when administered via conventional routes. There is a clear and critical need for the development of a novel delivery system that can efficiently deliver the drug to lung vasculature and minimize adverse effects. This article summarizes the inhalation devices and recent patents in the area of inhalable therapy for the treatment of PAH. Various patents are discussed that describe the application of inhalable therapy to target lung vasculature and to reduce dose-related side effects in PAH treatment. Entry of some inhalable delivery approaches into clinical trials is the result of progress in inhalable therapies for the treatment of PAH.


Asunto(s)
Hipertensión Pulmonar/terapia , Administración por Inhalación , Animales , Terapia Genética , Humanos , Hipertensión Pulmonar/metabolismo , Nebulizadores y Vaporizadores , Óxido Nítrico/administración & dosificación , Inhibidores de Fosfodiesterasa 5/administración & dosificación , Prostaglandinas/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA